Senior-COVID-Rea Multicentric Survey

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

185 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-04-01

Study Completion Date

2020-08-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

With the spread of COVID-19 epidemic since 2019 in Wuhan, China health plans have to be adapted continuously in response to the emergency. The first publications from the Chinese experience demonstrate an increase in the incidence of COVID-19 infections in patients over 60 years of age, a higher frequency of severe forms of the disease and therefore theoretical indications of orientation towards resuscitative care.

However, the first published data from Hubei province suggest a low benefit of resuscitation for patients between 70 and 80 years of age and null in patients over 80 years of age. These data question the individual benefit / risk balance of an orientation towards resuscitation for this category of patients, their quality of life and the concept of unreasonable obstinacy.

Among the covariates associated with resuscitation mortality described in the data published to date, cardiovascular comorbidities, certain biological covariates (LDH, creatinine, lymphocytes, neutrophils, TP, D-dimers, etc.), the time between the first symptoms and the entry into resuscitation have been identified.

The objective of this multicentric observational study is to determine the clinical and biological covariates predictive of mortality in the population of patients over 60 years of age admitted in intensive care unit, in particular by integrating functional and nutritional data from patients 1 month before COVID-19 infection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

One-year Outcomes in Survivors of the Severe COVID-19 Pneumonia (CO-Qo-ICU)

NCT04401111

COVID ARDS Quality of Life

RECRUITING

Impact of COVID-19 SARS-CoV-2 Variability in ICU Hospitalized Patients With Severe Disease

NCT05162508

SARS-CoV2 Infection COVID-19 Acute Respiratory Distress Syndrome Mutation

RECRUITING

Clinical Features of Severe Patients With COVID-19

NCT04450017

SARS-CoV2

COMPLETED

Outcomes and Prognostic Factors in COVID-19

NCT04321265

COVID-19 Elderly Patients Critical Illness +2 more

UNKNOWN

Epidemiological Investigation of CRBSI, VAP, CAUTI in Chinese ICU

NCT01943331

Nosocomial Infection

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Disease, Severe Form

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Group1

* Comorbidities (CIRS-G scale),
* Functional status of the patient with

* Clinical frailty scale (1 month before infection)
* ADL score (1 month before infection)
* Biological data

* Blood group
* TP, D-dimers, CRP, creatinine level at the patient's entry, triglyceridemia, fibrinogen, ferritin
* Parameters derived from the platelet formula count on D1 of the start of intensive care (lymphocytes, neutrophils, platelets, average platelet volume, red blood cell distribution index), SYSMEX data (IG: Immature granulocytes; HFLC: high fluorescent lymphocyte count)
* Resuscitation outcomes

* LDH rate at the start of intensive care
* PaO2 / FiO2 ratio at the start of intensive care
* IGSII / SASPII score (simplified acute physiology score) on D1 of the start of intensive care
* SOFA score (sepsis-related organ failure assessment): a posteriori estimate based on IGSII / SASPII
* Delay between the appearance of the first signs of infection and admission to intensive care